Tyrosine kinase inhibitors in sarcoma treatment (Review)
Anastasios Kyriazoglou(Alexandra Hospital), Amanda Psyrri(National and Kapodistrian University of Athens), Anastasios Pantazopoulos(University General Hospital Attikon), Georgios Kavourakis(University General Hospital Attikon), Ioanna Nixon(Beatson West of Scotland Cancer Centre), Μaria Anastasiou(National and Kapodistrian University of Athens), Ioannis Chatzidakis(University General Hospital Attikon), Ioannis Kotsantis(National and Kapodistrian University of Athens), Maria Prevezanou(University General Hospital Attikon), Lydia Evangelia Gkaralea(Hospital Agioi Anargyroi), Panagiota Economopoulou(National and Kapodistrian University of Athens)
Cited by 24
Related Papers
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.
|Head & Neck|2009|265
Tipifarnib in Head and Neck Squamous Cell Carcinoma With<i>HRAS</i>Mutations
|Journal of Clinical Oncology|2021|196
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
|Annals of Oncology|2022|148
Activation of Wnt Signaling Pathway by Human Papillomavirus E6 and E7 Oncogenes in HPV16-Positive Oropharyngeal Squamous Carcinoma Cells
|Molecular Cancer Research|2010|120